Preliminary results of a phase II neoadjuvant trial with gemcitabine/oxaliplatin and cetuximab followed by surgery or concurrent intensity modulated radiation therapy (IMRT) with capecitabine for patients with borderline resectable and unresectable nonmetastatic pancreatic cancer

被引：0
|
作者：
Chaudhary, U. B. [1 ]
Gudena, V. [1 ]
Milling, D. L. [1 ]
O'Brien, P. [1 ]
Montero, A. J. [1 ]
Brashears, J. [1 ]
Marshall, D. [1 ]
Hoffman, B. [1 ]
Garrett-Mayer, E. [1 ]
Esnaola, N. [1 ]
机构：
[1] Med Univ S Carolina, Charleston, SC 29425 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
15506
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Phase I/II Radiation Dose-Escalation Trial of Intensity Modulated Radiotherapy (IMRT) with Concurrent Fixed Dose-Rate Gemcitabine (FDR-G) for Unresectable Pancreatic Cancer
    Ben-Josef, E.
    Schipper, M.
    Francis, I.
    Khan, G.
    Hadley, S.
    Lawrence, T.
    Simeone, D.
    Abrams, R.
    Sonnenday, C.
    Zalupski, M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (02): : S127 - S128
  • [32] Phase I Trial Evaluating the Safety of Preoperative Gemcitabine/nab-Paclitaxel With Concurrent Radiation Therapy for Borderline Resectable Pancreatic Cancer
    Takahashi, Hidenori
    Akita, Hirofumi
    Ioka, Tatsuya
    Wada, Hiroshi
    Tomokoni, Akira
    Asukai, Kei
    Ohue, Masayuki
    Yano, Masahiko
    Ishikawa, Osamu
    PANCREAS, 2018, 47 (09) : 1135 - 1141
  • [33] Phase II study evaluating trimodal therapy with cetuximab intensity modulated radiotherapy (IMRT) and gemcitabine for patients with locally advanced pancreatic cancer [ISRCTN56652283].
    Krempien, R. C.
    Muenter, M. W.
    Timke, C.
    Huber, P. E.
    Friess, H.
    Heeger, S.
    Herfarth, K. K.
    Abdollahi, A.
    Hartung, G.
    Buchler, M. W.
    Debus, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 203S - 203S
  • [34] A phase II study of neoadjuvant gemcitabine/5-fluorouracil followed by 5-fluorouracil/oxaliplatin concurrent with radiation in patients with locally advanced pancreatic cancer.
    Lin, C.
    Kos, B. M.
    Sasson, A. R.
    Meza, J. L.
    Grem, J. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [35] Phase II Trial of Docetaxel and Cisplatin Neoadjuvant Chemotherapy Followed by Intensity Modulated Radiation Therapy With Concurrent Cisplatin in Advanced Nasopharyngeal Carcinoma
    Zhong, Y.
    Zhou, Y.
    Xie, C.
    Wang, X.
    Zhou, F.
    Chen, G.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (03): : S207 - S207
  • [36] CAPIRI-IMRT: a phase II study of concurrent capecitabine and irinotecan with intensity-modulated radiation therapy for the treatment of recurrent rectal cancer
    Cai, Gang
    Zhu, Ji
    Palmer, Joshua D.
    Xu, Ye
    Hu, Weigang
    Gu, Weilie
    Cai, Sanjun
    Zhang, Zhen
    RADIATION ONCOLOGY, 2015, 10
  • [37] CAPIRI-IMRT: a phase II study of concurrent capecitabine and irinotecan with intensity-modulated radiation therapy for the treatment of recurrent rectal cancer
    Gang Cai
    Ji Zhu
    Joshua D Palmer
    Ye Xu
    Weigang Hu
    Weilie Gu
    Sanjun Cai
    Zhen Zhang
    Radiation Oncology, 10
  • [38] Patterns of failure in a phase II trial of neoadjuvant chemotherapy and stereotactic body radiation therapy (SBRT) for resectable and borderline resectable (BLR) pancreatic cancer.
    Kharofa, Jordan
    Mierzwa, Michelle Lynn
    Olowokure, Olugbenga Olanrele
    Sussman, Jeffrey J.
    Latif, Tahir
    Gupta, Anumeha
    Esslinger, Hope
    Poreddy, Sampath
    Mcgill, Brian
    Wolf, Eric
    Smith, Milton T.
    Choe, Kyuran Ann
    Ahmad, Syed A.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [39] Phase II trial of neoadjuvant S-1 and concurrent radiotherapy for borderline resectable pancreatic cancer: Interim results of JASPAC05.
    Takahashi, Shinichiro
    Ohno, Izumi
    Ikeda, Masafumi
    Konishi, Masaru
    Kobayashi, Tatsushi
    Akimoto, Tetsuo
    Kojima, Motohiro
    Morinaga, Soichiro
    Ku, Yonson
    Shimizu, Yasuhiro
    Nakamori, Shoji
    Hishinuma, Shoichi
    Takakura, Norihisa
    Kainuma, Osamu
    Hirano, Satoshi
    Otsubo, Takehito
    Nagino, Masato
    Kimura, Wataru
    Yamashita, Yoichi
    Uesaka, Katsuhiko
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [40] Phase II study of oxaliplatin (OX), 5-fluorouracil (5-FU), and radiation therapy (RT) followed by gemcitabine (GEM) in patients with unresectable pancreatic cancer
    Kim, G. P.
    Haddock, M.
    Foster, N. R.
    Bollinger, J.
    Stella, P. J.
    Kugler, J. W.
    Alberts, S. R.
    Martenson, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345